1-5 of 5
Alison McCaig
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Talha Munir, Louise-Rae Cherrill, Nichola Webster, Surita Dalal, Rebecca H. Boucher, Chhaya Sankhalpara, Francesca Yates, Sonia Fox, Donald Macdonald, Christopher Fegan, Alison McCaig, Anna Schuh, Andrew Pettitt, John G. Gribben, Piers E.M. Patten, Stephen Devereux, Adrian Bloor, Christopher P Fox, Francesco Forconi, Andy C. Rawstron, Peter Hillmen
Journal: Blood
Blood (2022) 140 (Supplement 1): 222–223.
https://doi.org/10.1182/blood-2022-166700
Published: 2022
Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Nichola Webster, Surita Dalal, PhD, Kristian Brock, PhD, Francesca Yates, PhD, Chhaya Sankhalpara, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Christopher Fegan, Alison McCaig, MBChB, FRCPath, PhD MRCP, Anna Schuh, MD MRCP, PhD, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Piers Patten, MD PhD, Stephen Devereux, PhD FRCP, FRCPath, MRCPath, MB BS, Adrian Bloor, PhD FRCP, FRCPath, Christopher P Fox, PhD FRCPath, MRCP, MBChB, Francesco Forconi, MD PhD FRCPath, Andrew Rawstron, PhD, Peter Hillmen, MBChB, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-136960
Published: 2020
Journal Articles

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Andy Rawstron, BSc, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Donald Macdonald, Christopher Fegan, MD, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Stephen Devereux, PhD, Adrian Bloor, MA MB BChir PhDFCRP FRCPath, Christopher P. Fox, MD PhD, Francesco Forconi, MD DM, PhD FRCPath, Talha Munir
Journal: Blood
Blood (2018) 132 (Supplement 1): 182.
https://doi.org/10.1182/blood-2018-182
Published: 2018
Journal Articles

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Peter Hillmen, MBChB, PhD, Talha Munir, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Christopher Fegan, MD, Donald Macdonald, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, MDDSc FMedSci, Stephen Devereux, FRCP, FRCPath, PhD, Adrian Bloor, Christopher P Fox, MBChB PhD, Francesco Forconi, MD DM, PhD FRCPath
Journal: Blood
Blood (2017) 130 (Supplement 1): 428.
https://doi.org/10.1182/blood.V130.Suppl_1.428.428
Published: 2017
Journal Articles

Investigating the Efficacy of Ofatumumab and Rituximab in Abrogating the Survival of NOTCH1 Mutated Chronic Lymphocytic Leukaemic (CLL) Cells

Odette Middleton, Alison McCaig, Mike Leach, Alison Michie, Helen Wheadon
Journal: Blood
Blood (2014) 124 (21): 3289.
https://doi.org/10.1182/blood.V124.21.3289.3289
Published: 2014